It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
The decision was driven by results from the Phase III CAPItello-281 trial,
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
First installation of AI-powered AMULET SOPHINITY at NM Medical aims to strengthen early breast cancer detection
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
